Meloxicam can help reduce pain from a herniated disc, though the relief is typically modest rather than dramatic. It works by targeting the inflammatory process that makes a compressed nerve root painful, and it’s considered a standard first-line treatment alongside physical therapy. That said, the clinical evidence for NSAIDs in disc-related nerve pain is less clear-cut than many people expect.
How Meloxicam Targets Disc-Related Pain
When a disc herniates and presses on a spinal nerve root, the mechanical compression is only part of the problem. The body launches an inflammatory response around the injured nerve, and an enzyme called COX-2 ramps up at the injury site. This inflammation amplifies pain signals and can sustain them long after the initial injury. Meloxicam is a selective COX-2 inhibitor, meaning it blocks this specific enzyme more precisely than older anti-inflammatory drugs like ibuprofen, which shut down a broader range of inflammatory pathways.
Research from preclinical studies on nerve root compression shows meloxicam does more than just quiet inflammation at the injury site. It also reduces activation of immune-like cells in the spinal cord (called microglia and astrocytes) that amplify pain signaling centrally. By suppressing both the local inflammation around the compressed nerve and the secondary inflammatory cascade in the spinal cord, meloxicam addresses two layers of the pain problem simultaneously. This dual action is what makes it a reasonable choice for radiculopathy, the shooting leg or arm pain that comes from a pinched nerve root.
What the Evidence Actually Shows
Here’s where expectations need adjusting. While meloxicam clearly reduces inflammation, the clinical trial data for NSAIDs in sciatica and radiculopathy is surprisingly mixed. A large systematic review published in The BMJ pooled results from NSAID trials in sciatica patients and found no clear benefit in the first two weeks. Over a longer window of two weeks to three months, there was limited support from low-to-moderate quality evidence suggesting NSAIDs provide some short-term relief.
An observational study of meloxicam at 15 mg per day for acute back pain found that the average treatment course lasted about 8 to 9 days, with pain relief assessed at the two-week mark. That lines up with the general timeline: you shouldn’t expect overnight results. Most people begin noticing some improvement within the first week, with fuller anti-inflammatory effects building over several days of consistent use.
The honest takeaway is that meloxicam helps take the edge off disc-related pain for many people, but it’s unlikely to eliminate it on its own. It works best as one piece of a broader approach that includes activity modification, physical therapy, and time, since most herniated discs improve substantially over weeks to months regardless of medication.
Where It Fits in the Treatment Ladder
Clinical guidelines consistently place NSAIDs like meloxicam as a first-line option for herniated disc pain. Non-surgical management with anti-inflammatories and physical therapy remains the standard starting point for acute radiculopathy, and most people never need to escalate beyond this. Simple pain relievers like acetaminophen were previously recommended as the initial step, but guidelines published after 2016 have shifted toward favoring NSAIDs earlier in treatment.
If meloxicam alone isn’t providing enough relief after a couple of weeks, the next steps typically involve adding other approaches: a short course of oral steroids, epidural steroid injections, or stronger pain medications for severe cases. Surgery is reserved for people with persistent symptoms after several months of conservative care, or for those with progressive neurological problems like worsening weakness or loss of bladder control.
Meloxicam vs. Other Anti-Inflammatories
If you’re wondering whether meloxicam is better than ibuprofen, naproxen, or another NSAID, the evidence says probably not in terms of pain relief. A Cochrane review of NSAIDs for back pain found no difference in effectiveness between selective COX-2 inhibitors (like meloxicam) and non-selective NSAIDs (like ibuprofen or naproxen). One type doesn’t outperform another for reducing pain.
The difference is in side effects. Non-selective NSAIDs carry a higher risk of stomach problems because they block COX-1, an enzyme that helps protect the stomach lining. Meloxicam’s selectivity for COX-2 gives it a somewhat gentler profile on the digestive system, which matters if you’re taking it for more than a few days. That’s often the practical reason a doctor chooses meloxicam over ibuprofen for disc pain: it’s not more effective, but it may be easier to tolerate over a treatment course of one to two weeks.
How to Take It Effectively
The standard dose for disc-related pain is 15 mg once daily, taken by mouth. You can take it with or without food, though taking it with a meal can reduce the chance of stomach upset. A typical course runs one to two weeks for an acute flare, though your prescriber may adjust this based on your response.
One important rule: don’t combine meloxicam with other NSAIDs like ibuprofen, naproxen, or aspirin. Stacking anti-inflammatories doesn’t improve pain relief but significantly increases the risk of stomach ulcers and gastrointestinal bleeding. If you’ve been taking over-the-counter ibuprofen and your doctor prescribes meloxicam, stop the ibuprofen.
Who Should Be Cautious
Meloxicam isn’t appropriate for everyone with a herniated disc. People who have had a recent heart attack should avoid it unless specifically directed otherwise. It also shouldn’t be taken around or after 20 weeks of pregnancy due to risks to the fetus and complications with delivery. If you have a known allergy to aspirin or other NSAIDs, meloxicam is off the table since cross-reactivity is common across the NSAID class.
People with a history of stomach ulcers, kidney problems, or cardiovascular disease need to weigh the risks carefully. Even with meloxicam’s relative stomach-friendliness compared to older NSAIDs, it still carries gastrointestinal and cardiovascular risks that increase with longer use and higher doses. For short courses of one to two weeks at a standard dose, serious complications are uncommon in otherwise healthy adults, but the risk isn’t zero.